SMT202200167T1 - Rilevamento e trattamento del deficit dell’ormone della crescita - Google Patents

Rilevamento e trattamento del deficit dell’ormone della crescita

Info

Publication number
SMT202200167T1
SMT202200167T1 SM20220167T SMT202200167T SMT202200167T1 SM T202200167 T1 SMT202200167 T1 SM T202200167T1 SM 20220167 T SM20220167 T SM 20220167T SM T202200167 T SMT202200167 T SM T202200167T SM T202200167 T1 SMT202200167 T1 SM T202200167T1
Authority
SM
San Marino
Prior art keywords
detection
treatment
growth hormone
hormone deficiency
deficiency
Prior art date
Application number
SM20220167T
Other languages
English (en)
Italian (it)
Inventor
Michael Thorner
Original Assignee
Lumos Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lumos Pharma Inc filed Critical Lumos Pharma Inc
Publication of SMT202200167T1 publication Critical patent/SMT202200167T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/61Growth hormones [GH] (Somatotropin)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/65Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SM20220167T 2015-09-21 2016-09-21 Rilevamento e trattamento del deficit dell’ormone della crescita SMT202200167T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562221191P 2015-09-21 2015-09-21
US201662289221P 2016-01-30 2016-01-30
EP16849470.6A EP3352752B1 (en) 2015-09-21 2016-09-21 Detecting and treating growth hormone deficiency
PCT/US2016/052800 WO2017053373A1 (en) 2015-09-21 2016-09-21 Detecting and treating growth hormone deficiency

Publications (1)

Publication Number Publication Date
SMT202200167T1 true SMT202200167T1 (it) 2022-05-12

Family

ID=58276481

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20220167T SMT202200167T1 (it) 2015-09-21 2016-09-21 Rilevamento e trattamento del deficit dell’ormone della crescita

Country Status (23)

Country Link
US (5) US9763919B2 (https=)
EP (3) EP3352752B1 (https=)
JP (5) JP6816149B2 (https=)
KR (4) KR20250102122A (https=)
CN (2) CN116459250A (https=)
AU (5) AU2016328969B2 (https=)
CA (1) CA2998523C (https=)
CY (1) CY1125183T1 (https=)
DK (2) DK3939590T3 (https=)
ES (2) ES2967259T3 (https=)
FI (1) FI3939590T3 (https=)
HR (1) HRP20220317T1 (https=)
HU (2) HUE057831T2 (https=)
IL (1) IL258224B (https=)
LT (1) LT3352752T (https=)
PL (2) PL3352752T3 (https=)
PT (2) PT3939590T (https=)
RS (1) RS62988B1 (https=)
SG (2) SG10202010598SA (https=)
SI (1) SI3352752T1 (https=)
SM (1) SMT202200167T1 (https=)
UA (1) UA123865C2 (https=)
WO (1) WO2017053373A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11234969B2 (en) * 2016-01-30 2022-02-01 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
HUE057831T2 (hu) * 2015-09-21 2022-06-28 Lumos Pharma Inc Növekedési hormon hiányának felismerése és kezelése
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
WO2020041322A1 (en) 2018-08-20 2020-02-27 Berkowitz Barry A Novel cannabinoids and cannabinoid acids and their derivatives
US11644474B2 (en) * 2020-07-22 2023-05-09 Æterna Zentaris Gmbh Use of macimorelin in assessing growth hormone deficiency in children
KR20250107210A (ko) * 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000759A1 (en) * 1992-06-29 1994-01-06 University Of South Florida Diagnostic procedure for evaluating short stature etiology
US5756507A (en) * 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
ATE344667T1 (de) 1997-08-22 2006-11-15 Kaken Pharma Co Ltd Amide zur förderung der ausschüttung von wachstumshormonen
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
AR029941A1 (es) 2000-06-13 2003-07-23 Zentaris Gmbh Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen
BRPI0414175A (pt) * 2003-09-19 2006-10-31 Pfizer Health Ab método melhorado de tratamento de distúrbios do crescimento
NZ547752A (en) 2003-11-12 2009-12-24 Phenomix Corp Heterocyclic boronic acid compounds for inhibiting dipeptidyl peptidase-IV
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
WO2013163455A2 (en) * 2012-04-25 2013-10-31 The Regents Of The University Of California A drug screening platform for rett syndrome
US11234969B2 (en) * 2016-01-30 2022-02-01 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
HUE057831T2 (hu) * 2015-09-21 2022-06-28 Lumos Pharma Inc Növekedési hormon hiányának felismerése és kezelése

Also Published As

Publication number Publication date
KR102560838B1 (ko) 2023-07-27
JP7724831B2 (ja) 2025-08-18
PT3939590T (pt) 2024-01-23
JP7104768B2 (ja) 2022-07-21
AU2021254600A1 (en) 2021-11-18
KR20220047407A (ko) 2022-04-15
IL258224A (en) 2018-05-31
AU2020233715A1 (en) 2020-10-22
PL3352752T3 (pl) 2022-04-19
JP6816149B2 (ja) 2021-01-20
KR20230116961A (ko) 2023-08-04
US20190015394A1 (en) 2019-01-17
JP2024026112A (ja) 2024-02-28
EP3939590A1 (en) 2022-01-19
PT3352752T (pt) 2022-03-09
US10105352B2 (en) 2018-10-23
DK3939590T3 (da) 2023-12-18
NZ741142A (en) 2025-05-02
AU2024201658A1 (en) 2024-04-04
FI3939590T3 (fi) 2023-12-14
SI3352752T1 (sl) 2022-05-31
AU2024201658C1 (en) 2026-02-12
AU2025237934A1 (en) 2025-10-16
US20180071266A1 (en) 2018-03-15
KR102385669B1 (ko) 2022-04-13
HUE065224T2 (hu) 2024-05-28
JP7389862B2 (ja) 2023-11-30
IL258224B (en) 2021-10-31
HUE057831T2 (hu) 2022-06-28
CN116459250A (zh) 2023-07-21
US10898472B2 (en) 2021-01-26
JP2021063096A (ja) 2021-04-22
EP3352752A1 (en) 2018-08-01
UA123865C2 (uk) 2021-06-16
EP4296679A3 (en) 2024-04-10
AU2020233715B2 (en) 2021-09-30
CA2998523C (en) 2023-08-01
US20220142989A1 (en) 2022-05-12
US20250213536A1 (en) 2025-07-03
HRP20220317T1 (hr) 2022-05-13
PL3939590T3 (pl) 2024-03-25
HK1263178A1 (zh) 2020-01-31
LT3352752T (lt) 2022-04-11
ES2908423T3 (es) 2022-04-29
EP3939590B1 (en) 2023-11-29
KR20250102122A (ko) 2025-07-04
KR20180082428A (ko) 2018-07-18
US20170079961A1 (en) 2017-03-23
RS62988B1 (sr) 2022-03-31
AU2016328969A1 (en) 2018-04-26
CN108348501A (zh) 2018-07-31
EP3352752A4 (en) 2019-06-12
SG10201902424TA (en) 2019-04-29
CY1125183T1 (el) 2023-06-09
EP3352752B1 (en) 2021-12-22
DK3352752T3 (da) 2022-02-28
SG10202010598SA (en) 2020-11-27
JP2022163012A (ja) 2022-10-25
CA2998523A1 (en) 2017-03-30
JP2018529766A (ja) 2018-10-11
WO2017053373A1 (en) 2017-03-30
AU2021254600B2 (en) 2024-02-15
AU2016328969B2 (en) 2020-10-08
ES2967259T3 (es) 2024-04-29
US9763919B2 (en) 2017-09-19
EP4296679A2 (en) 2023-12-27
US12539293B2 (en) 2026-02-03
AU2024201658B2 (en) 2025-10-30
JP2025170274A (ja) 2025-11-18

Similar Documents

Publication Publication Date Title
IL282048A (en) Oxysterols and methods of use thereof
IL253162A0 (en) Compositions and methods for treatment and detection of cancers
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
PL3402888T3 (pl) Środki i sposoby leczenia hbv
DK3259597T3 (da) Pvrig-polypeptider og fremgangsmåder til behandling
EP3302442C0 (en) DOSAGE FORMS AND THEIR USE
EP3359171C0 (en) Use of akkermansia muciniphila for treating inflammatory conditions
PL3828194T3 (pl) Oksysterole i sposoby ich stosowania
PL3283527T3 (pl) Leczenie skojarzone nowotworów
DK3205650T3 (da) Egfr-hæmmer og fremstilling og anvendelse deraf
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
PL3362084T3 (pl) Urządzenia do podawania dojelitowego i powiązane sposoby zastosowania
PL3973959T3 (pl) Leczenie świądu cholestatycznego za pomocą seladelparu
EP3334429C0 (en) HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR
LT3341027T (lt) Transfekcijos kompleksai ir jų panaudojimo būdai
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
SMT202200167T1 (it) Rilevamento e trattamento del deficit dell’ormone della crescita
DK3347016T3 (da) Diagnosticering og behandling af angstlidelse
DK3142664T3 (da) Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme
DK3265641T3 (da) Stigørenhed og fremgangsmåde
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
IL257355B (en) Selection of patients for combination therapy
LT3576740T (lt) Vėžio gydymas
DK3185872T3 (da) Formulering af testosteron og metoder til behandling hermed
IL254825A0 (en) Methods of treatment with taselisib